Stocktoria
ENDRA Life Sciences Inc. NDRA
ENDRA Life Sciences Inc. (NDRA) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NDRA | ENDRA Life Sciences Inc. | 2/9 | — | — | — |
| MDT | Medtronic plc | 7/9 | 3.76 | 21.6 | +8.4% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
FAQ
Is NDRA financially healthy?
ENDRA Life Sciences Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does NDRA pay a dividend?
No, ENDRA Life Sciences Inc. does not currently pay a dividend.
How profitable is NDRA?
In FY2025, ENDRA Life Sciences Inc. had a return on equity of -310.9%.
What is the analyst price target for NDRA?
The average Wall-Street price target for ENDRA Life Sciences Inc. is $25.00, about 459.3% above the recent price, from 1 analysts.
Is NDRA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ENDRA Life Sciences Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.